The biggest obstacle for med-tech giant Medtronic (MDT) today is not its competition nor the still-sleepy markets for medical procedures. Instead, the biggest problem Medtronic has is a market/investor base that seems unwilling to accept the company for what it is. Medtronic came in shy of the more robust growth expectations this quarter, but even modest long-term growth projections suggest these shares are undervalued today.
Fiscal Q3 Comes In Evenly Light...
At least a few sell-side analysts had been trying to make the case that this would be the quarter where Medtronic would make the turn and re-establish good mid-single digit organic growth credentials. That didn't come to pass, though, as Medtronic had a pretty "meh" quarter across...